Our impact
Investment in the Catapult network, by Innovate UK, is an economic initiative and we have a clear model for achieving and demonstrating economic impact.

It is our mandate to catalyse and facilitate growth in the cell and gene therapy industry. Since our inception in 2012, we have been gathering qualitative and quantitative data to showcase the impact we are having on the companies and researchers we work with and on general industry growth.

UK companies have received
£2.5bn+investment

There are
70+
ATMP developers in the UK compared to 22 in 2012

Of UK ATMP developers
73%
are collaborating with CGT Catapult

There are
127
active clinical trials in 2019, compared to 85 in 2018

There has been
45%
growth in UK clinical trials

There are
3,000+
jobs compared to 540 in 2012

There are
26
GMP facilities compared to 11 in 2012

There has been
136%
increase in the number of GMP manufacturing facilities

The
7,700m2
CGT Catapult manufacturing centre opened in 2018

Discover who we are